LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a

Bladder cancer (BC) ranks as the most prevalent malignant neoplasm affecting the urinary system. However, its clinical prevention and treatment continue to face significant challenges. This research aims to investigate the biological roles and regulatory mechanisms of FRMD6-AS2 in BC. Tissue samples were collected from 132 BC patients, along with their matched adjacent normal tissues. Quantitative reverse transcription polymerase chain reaction was employed to determine FRMD6-AS2 and miR-1260a expression, and their correlation was assessed using Pearson correlation analysis. The link between FRMD6-AS2 and patient prognosis was analyzed via Kaplan-Meier and Cox regression analyses to identify independent prognostic factors. Cell proliferation, migration, invasion, and apoptosis were determined by employing the cell counting kit-8, Transwell, and Annexin V-fluorescein isothiocyanate/ propidium iodide assays. The direct binding interaction between FRMD6-AS2 and miR-1260a was verified by luciferase reporter and RNA immunoprecipitation assays. FRMD6-AS2 was lowly expressed in BC tissues and cells. Patients with low FRMD6-AS2 expression exhibited poorer overall survival, and it was identified as an independent prognostic factor. Overexpression of FRMD6-AS2 led to the inhibition of BC cell proliferation, migration, and invasion while promoting apoptosis. Mechanistically, FRMD6-AS2 negatively regulated miR-1260a expression. Furthermore, overexpression of miR-1260a partially reversed the suppressive impacts of FRMD6-AS2 on the malignant behaviors of BC cells. FRMD6-AS2 exhibits reduced expression in BC and plays tumor-suppressive effects by sponging miR-1260a, suggesting its potential as a prognostic biomarker and therapeutic target for BC.